Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer
Journal of Clinical Oncology2013Vol. 31(7), pp. 895–902
Citations Over TimeTop 1% of 2013 papers
James W. Welsh, Ritsuko Komaki, Arya Amini, Mark F. Munsell, Wyatt Unger, Pamela K. Allen, Joe Y. Chang, Jeffrey S. Wefel, Susan L. McGovern, Linda L. Garland, Su S. Chen, J.A. Holt, Zhongxing Liao, Paul D. Brown, Erik P. Sulman, John V. Heymach, Edward S. Kim, Baldassarre Stea
Abstract
Erlotinib was well tolerated in combination with WBRT, with a favorable objective response rate. The higher-than-expected rate of EGFR mutations in these unselected patients raises the possibility that EGFR-mutated tumors are prone to brain dissemination.
Related Papers
- → Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma(2012)30 cited
- → Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts(2011)14 cited
- → Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC Trial(2015)9 cited
- → Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous Toxicity(2009)21 cited
- The correlation between skin rash and the effi cacy of erlotinib in patients with advanced non-small cell lung cancer(2009)